ATE266409T1 - Synergistische wirkung von glyburide und milrinone - Google Patents

Synergistische wirkung von glyburide und milrinone

Info

Publication number
ATE266409T1
ATE266409T1 AT01303020T AT01303020T ATE266409T1 AT E266409 T1 ATE266409 T1 AT E266409T1 AT 01303020 T AT01303020 T AT 01303020T AT 01303020 T AT01303020 T AT 01303020T AT E266409 T1 ATE266409 T1 AT E266409T1
Authority
AT
Austria
Prior art keywords
sulfonylurea
diabetic
channel blocker
atp channel
inhibitor
Prior art date
Application number
AT01303020T
Other languages
English (en)
Inventor
David Albert Fryburg
Janice Catherine Parker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE266409T1 publication Critical patent/ATE266409T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT01303020T 2000-04-13 2001-03-30 Synergistische wirkung von glyburide und milrinone ATE266409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19672800P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
ATE266409T1 true ATE266409T1 (de) 2004-05-15

Family

ID=22726606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01303020T ATE266409T1 (de) 2000-04-13 2001-03-30 Synergistische wirkung von glyburide und milrinone

Country Status (12)

Country Link
US (2) US6610746B2 (de)
EP (1) EP1145717B1 (de)
JP (1) JP2001354568A (de)
AT (1) ATE266409T1 (de)
BR (1) BR0101461A (de)
CA (1) CA2343850A1 (de)
DE (1) DE60103203T2 (de)
DK (1) DK1145717T3 (de)
ES (1) ES2218338T3 (de)
MX (1) MXPA01003853A (de)
PT (1) PT1145717E (de)
TR (1) TR200401145T4 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
WO2003012030A2 (en) 2001-08-01 2003-02-13 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003222020B2 (en) 2002-03-20 2008-08-28 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
AU2003234929A1 (en) * 2002-05-17 2003-12-02 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
EP1722120A4 (de) * 2004-03-02 2012-10-24 Ntn Toyo Bearing Co Ltd Rotationsübertragungsvorrichtung
JP5078350B2 (ja) * 2004-03-04 2012-11-21 キッセイ薬品工業株式会社 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
WO2005102304A1 (en) * 2004-04-23 2005-11-03 Northern Sydney And Central Coast Area Health Service Methods and compositions for the treatment of myocardial conditions
EP1799227B1 (de) 2004-09-18 2010-11-10 University of Maryland, Baltimore Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
CN101043891A (zh) * 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
EP2114160B1 (de) * 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonisten eines nicht selektiven kationenkanals in nervenzellen
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
JP2010168301A (ja) * 2009-01-22 2010-08-05 Kitasato Institute 中枢循環改善薬
CN103372013A (zh) * 2013-06-28 2013-10-30 上海交通大学医学院附属瑞金医院 米力农在制备治疗糖尿病足溃疡药物方面的应用
US11260074B2 (en) 2014-03-26 2022-03-01 Enrique G. Gutierrez Compositions and related methods for reconstituting the immune system of a subject
US10624923B2 (en) 2014-03-26 2020-04-21 Enrique G. Gutierrez Compositions and related methods for treating and preventing viral and retroviral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
DK1145717T3 (da) 2004-08-02
DE60103203T2 (de) 2005-05-04
EP1145717A3 (de) 2002-08-14
PT1145717E (pt) 2004-08-31
US20030216294A1 (en) 2003-11-20
EP1145717B1 (de) 2004-05-12
US6610746B2 (en) 2003-08-26
ES2218338T3 (es) 2004-11-16
MXPA01003853A (es) 2005-06-30
US20020013268A1 (en) 2002-01-31
EP1145717A2 (de) 2001-10-17
TR200401145T4 (tr) 2004-07-21
DE60103203D1 (de) 2004-06-17
CA2343850A1 (en) 2001-10-13
JP2001354568A (ja) 2001-12-25
BR0101461A (pt) 2001-11-13

Similar Documents

Publication Publication Date Title
ATE266409T1 (de) Synergistische wirkung von glyburide und milrinone
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
MXPA05011702A (es) Agentes antidiabeticos.
BR0112522A (pt) Agonistas receptores adrenérgicos de fenilamina beta-3 cìclica
IL118474A0 (en) Benzimidazole derivatives pharmaceutical compositions containing the same and the use thereof
ATE143002T1 (de) Aromatische aminoalkoholderivate mit antidiabetischer und antiobesitäts-wirkung, ihre herstellung und therapeutische verwendung
DK1088824T3 (da) Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
KR890002155A (ko) 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법
UY26909A1 (es) Derivados de pirazol
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
BR0300314A (pt) Agentes antidiabéticos
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
BR0215032A (pt) Composição herbicidamente ativa, método para controlar vegetação indesejável, e, uso de composições
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
ATE518544T1 (de) Rotbusch-extrakt gegen diabetes
BR0107902A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
BR0209650A (pt) Análogos de adenosina para o tratamento da sìndrome de resistência à insulina e da diabetes
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes
BR9913149A (pt) Derivados de piperazina antidiabéticos, processos para sua preparação e composições contendo os mesmos
RS20050776A (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment diabetes
ATE380799T1 (de) Biguanid-derivate und deren verwendung als antidiabetika

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1145717

Country of ref document: EP

REN Ceased due to non-payment of the annual fee